Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies
October 17, 2022
0
Gilead Sciences and MacroGenics Collaboration Announcement Gilead Sciences (GILD) and MacroGenics (MGNX) announced an exclusive option and collaboration agreement to develop MGD024 using MacroGenics DART . . . This content is for paid subscribers. Please click here to subscribe or here to log in.